PAP
RCUS icon

Persistent Asset Partners’s Arcus Biosciences RCUS Stock Holding History

Persistent Asset Partners’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.3M Buy
+60,203
New +$1.3M 0.48% 52
2025
Q1 		– Sell
-50,213
Closed -$648K – 205
2024
Q4 		$648K Buy
+50,213
New +$820K 0.54% 52

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Persistent Asset Partners's RCUS Position: Q1 2026 in Review

Persistent Asset Partners opened a new position in Arcus Biosciences (RCUS) in Q1 2026: 60,203 shares worth $1.3M. The stake represents 0.48% of the portfolio and ranks #52 among its holdings. This is a return to the name: Persistent Asset Partners previously reported a position in RCUS as recently as Q4 2024.

Persistent Asset Partners first reported a position in RCUS in Q4 2024 and has held it in 2 quarters since. 210 funds tracked by Wall St. Rank hold RCUS as of Q1 2026.

  • Persistent Asset Partners held 60,203 shares of Arcus Biosciences worth $1.3M as of Q1 2026.
  • Arcus Biosciences was a new Persistent Asset Partners position in Q1 2026.
  • Arcus Biosciences made up 0.48% of Persistent Asset Partners's portfolio in Q1 2026, its #52 holding.
  • Persistent Asset Partners first reported a position in Arcus Biosciences in Q4 2024 and has held it in 2 quarters since.
  • 210 funds tracked by Wall St. Rank held Arcus Biosciences as of Q1 2026.

Based on Persistent Asset Partners's 13F filing for Q1 2026, filed 12 May 2026.